Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023
February 23 2023 - 4:31PM
Business Wire
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases, today announced
that it plans to release 2022 financial results and provide a
corporate update on March 2, 2023. The Company will host a
conference call at 4:30pm ET (1:30pm PT) on the same day.
CONFERENCE CALL DETAILS:
Live Call Participation: To join the live call by phone,
please pre-register via this link, complete the brief online
registration form, and select your preferred method for joining the
call. Upon registering you will receive the dial-in info and a
unique PIN to join the call, as well as an email confirmation with
the details. Please register at least 10 minutes prior to the event
to ensure timely access.
Live & Archived Webcast: To access a live or archived
webcast of the event, please visit the “Events & Presentations”
page within the Investors Relations section of Longboard’s website
at https://ir.longboardpharma.com/. An archived webcast of the call
will be available shortly after the event concludes and archived on
the website for at least 30 days following the event.
ABOUT LONGBOARD PHARMACEUTICALS
Longboard Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on developing novel,
transformative medicines for neurological diseases. Longboard is
working to advance a portfolio of centrally acting product
candidates designed to be highly selective for specific G
protein-coupled receptors (GPCRs). Longboard’s small molecule
product candidates are based on more than 20 years of GPCR
research. Longboard is evaluating LP352, an oral, centrally acting
5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no
observed impact on 5-HT2B and 5-HT2A receptor subtypes, in
development for the potential treatment of seizures associated with
a broad range of developmental and epileptic encephalopathies.
Longboard is also evaluating LP659, a centrally acting,
sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator,
which is in development for the potential treatment of multiple
neurological diseases.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release are forward-looking
statements that involve a number of risks and uncertainties. Such
forward-looking statements include statements about Longboard’s
upcoming call, Longboard’s clinical and preclinical programs,
ability to develop and deliver medicines, and focus. For such
statements, Longboard claims the protection of the Private
Securities Litigation Reform Act of 1995. Actual events or results
may differ materially from Longboard’s expectations. Factors that
could cause actual results to differ materially from those stated
or implied by Longboard’s forward-looking statements are disclosed
in Longboard’s filings with the Securities and Exchange Commission
(SEC). These forward-looking statements represent Longboard’s
judgment as of the time of this release. Longboard disclaims any
intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230223006003/en/
CORPORATE CONTACT: Megan E. Knight Head of Investor
Relations mknight@longboardpharma.com IR@longboardpharma.com
619.592.9775
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longboard Pharmaceuticals (NASDAQ:LBPH)
Historical Stock Chart
From Jul 2023 to Jul 2024